European Primary Care Cardiovascular Society

Spain - EPCCS Introduction

June 19, 2018

Lower Extremity Artery Disease: a neglected major CV disease: Diagnosis and clinical management in primary care

Mar. 15, 2018 - EPCCS 2018, Barcelona, Spain - Dr. Rafel Ramos (Girona, Spain)

Lipid lowering: the evidence, the guidelines, the clinical reality

Mar. 17, 2018 - EPCCS 2018, Barcelona, Spain - Dr. Monika Hollander, prof. Frank Visseren, dr. Jan Oltrogge

Management of CV risk that comes with T2DM in light of novel treatment options

Mar. 15, 2018 - EPCCS 2018, Barcelona, Spain - Dr. Carlos Brotons, prof. Xavier Cos, prof. Richard Hobbs

Treatment of high-risk ACS patients may change based on ODYSSEY OUTCOMES study results

Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA

Pharmacist intervention in American 'black barbershops' effective at lowering BP

Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Ronald Victor, MD - Los Angeles, CA, USA

PCSK9 inhibitor has very good benefit-to-risk profile in high risk ACS patients in ODYSSEY OUTCOMES trial

Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Prof. Gabriel Steg - Paris, France

Striking results for weight reduction in T2DM in primary care based program

Dec. 18, 2017 - IDF 2017 - Abu Dhabi, UAE - Prof Naveed Sattar, MD - Glasgow, UK

Clinical outcomes and adverse effects comparable across various BP measurement methods in SPRINT

Nov. 20, 2017 - AHA 2017 - Anaheim, CA, USA - Dr. Sripal Bangalore - NYU Langone, New York, NY, USA.

Good BP measurement depends more on appropriate technique than on absence of staff

Nov. 25, 2017 - AHA 2017 - Anaheim, CA, USA - Prof Karen Johnson - Memphis, TN, VS

Things to consider when aiming to prevent stroke in a patient with AF

May 25, 2017
##SCROLLER_ITEMS_FULL_TITLE##

What can be learned from the latest hypertension trials?

May 26, 2017
##SCROLLER_ITEMS_FULL_TITLE##

Heart failure diagnosis and management varies substantially across European countries

May 25, 2017

How do the latest guideline changes affect management of dyslipidaemia in primary care?

May 26, 2017
##SCROLLER_ITEMS_FULL_TITLE##

Ingredients of effective strategies to stimulate behaviour change

May 25, 2017

The evidence base for health behaviour changes

Dec. 9, 2015 - EPCCS 2015 - Prague, Czech Republic

Identifying and treating patients with true hypertension

Feb. 24, 2016 - Prague - EPCCS 2015

What is the evidence base for lipid modification in the guidelines updates?

Feb. 24, 2016 - Prague - EPCCS 2015
##SCROLLER_ITEMS_FULL_TITLE##

Heart failure diagnosis and management

Dec. 9, 2015 - EPCCS 2015 - Prague

​Stroke prevention in atrial fibrillation

Mar. 12, 2014 - Amsterdam - Hobbs, Rutten

Exaggerated BP response to exercise in hypertensives with controlled resting BP

June 20, 2018 - Chant B, et al. - Hypertension 2018

BP responses to exercise are similar in treated–controlled, treated-uncontrolled, and untreated hypertensives but higher compared with normotensives.

Risk of dementia increases with hypertension duration in mid-life

June 19, 2018 - Abell JG et al. - Eur Heart J 2018

Individuals with hypertension at mid-life, defined as SBP ≥130 mmHg at the age of 50, have an increased risk of dementia, which is proportional to the duration of the exposure to hypertension

New 2018 ESC/ESH Guidelines for treatment of hypertension - a first look

June 14, 2018 - news

Before publication later this year, a first look at the new 2018 ESC/ESH Guidelines of hypertension was presented. One of the key messages was the unchanged definition of hypertension of BP >140/90 mmHg.

High CV risk in obese women even in the absence of metabolic abnormalities

June 13, 2018 - Eckel N, et al. - Lancet Diab Endocrin 2018

CV risk is high in obese women without metabolic abnormalities, as well as in women with hypertension, diabetes or hypercholesterolemia, independently of their body mass index.

Positive association of alcohol intake with risk of stroke subtypes and inverse association with non-fatal CHD risk

June 11, 2018 - Ricci C, et al. - BMJ 2018

Both baseline and lifetime alcohol intake were inversely associated with the risk of non-fatal CHD, and positively associated with the risk of ischemic and hemorrhagic stroke.

No use of vitamin supplementation for CVD prevention, according to large meta-analysis

June 6, 2018 - Jenkins DJA et al., - J Am Coll Cardiol. 2018

No consistent benefit was seen of popular supplements (multivitamins, vitamin D, calcium and vitamin C) for the prevention of CVD, myocardial infarction or stroke, or on all-cause mortality.

Lower Extremity Artery Disease: a neglected major CV disease: Diagnosis and clinical management in primary care

Mar. 15, 2018 - EPCCS 2018, Barcelona, Spain - Dr. Rafel Ramos (Girona, Spain)
**EPCCS 2018** This is a brief version of the presentation that dr. Ramos gave on peripheral artery disease and associated risks and how it can best be managed.

EPCCS 2018 This is a brief version of the presentation that dr. Ramos gave on peripheral artery disease and associated risks and how it can best be managed.

High sustained CV risk up to 5 years after TIA or minor stroke

May 31, 2018 - Amarenco P, et al. - New Engl J Med 2018

Patients with a transient ischemic attack or minor stroke had a sustained elevated risk of CV events up to 5 years after the first event, and approximately half of these events occurred after the first year.

Superior improvement of HbA1c with GLP-1 receptor agonist compared to SGLT2 inhibitor

May 30, 2018 - news

Results from the PIONEER 2 trial in T2DM patients demonstrated a significant and superior improvement in HbA1c with semaglutide compared to empagliflozin.

GRAND DEBATE | Is HFmrEF similar to HFrEF?

ESC Heart Failure 2018, Vienna
ESC Heart Failure 2018, Vienna

ESC 2018 In this debate, it became clear that not all are convinced yet about the use of the new ejection fraction category HFmrEF that was introduced in the latest ESC HF Guidelines in 2016.

In past 3 decades much progress in HF therapy has been made, especially with combination therapy

May 29, 2018 - news
A network meta-analysis showed that incremental use of disease-modifying therapies lowers hospitalisations and mortality, which supports guideline recommendations.

ESC HF 2018 A network meta-analysis showed that incremental use of disease-modifying therapies lowers hospitalisations and mortality, which supports guideline recommendations.

Benefit from RAS inhibition in octogenarians with HFrEF

May 29, 2018 - news
SwedeHF data show that RASi is associated with reduced morbidity and mortality in HF patients of 80 years and older. Absolute risk reduction is larger than in younger HF patients.

ESC HF 2018 SwedeHF data show that RASi is associated with reduced morbidity and mortality in HF patients of 80 years and older. Absolute risk reduction is larger than in younger HF patients.